Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer

KRAS is frequently mutated in non-small cell lung cancer (NSCLC). However, direct targeting of KRAS has proven to be challenging, and inhibition of KRAS effectors has resulted in limited clinical efficacy. Wee1 kinase is an important regulator of the G2 checkpoint and is overexpressed in various can...

Descripción completa

Detalles Bibliográficos
Autores principales: Ku, Bo Mi, Bae, Yeon-Hee, Koh, Jiae, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620191/
https://www.ncbi.nlm.nih.gov/pubmed/28978051
http://dx.doi.org/10.18632/oncotarget.18728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620191/
https://www.ncbi.nlm.nih.gov/pubmed/28978051
http://dx.doi.org/10.18632/oncotarget.18728

Ejemplares similares